Grazoprevir (Single Agent) + Pitavastatin = Precautionary

Effect on Concentration

Grazoprevir (Single Agent)
No change
Applies within class?
No
Pitavastatin
Increase
Applies within class?
No

Pharmacologic Effects

Grazoprevir (Single Agent)
Effect
N/A
Applies within class?
No
Pitavastatin
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 22-Nov-2022

Summary

When coadministering grazoprevir and pitavastatin, monitoring for signs and symptoms of statin toxicity such as myopathy or rhabdomyolysis, etc. is recommended.

Sources

Grazoprevir (single agent) vs pitavastatin, midazolam, or atorvastatin ^

Study Design

The potential for grazoprevir (formerly known as MK-5172) to inhibit the organic anion transport proteins (OATP) in vivo was evaluated in a study using pitavastatin, a probe substrate for OATP. In an open label study, 9 healthy patients with ages 18-55 years old were given a single dose of pitavastatin 1 mg followed by 2-day washout. Then, they received grazoprevir 200mg daily for 9 days together with a single dose of 1 mg pitavastatin on Day 7.

Study Results

When healthy patients were given grazoprevir 200mg/day for 9 days together with a single dose of pitavastatin 1 mg, the AUC (95% CI) of pitavastatin was increased by 11% [ -9 %, 34 %]. Additionally, authors concluded that pitavastatin did not significantly affect PK of grazoprevir; however, no specific values were indicated.

Study Conclusions

References

Luzelena Caro, Jennifer E Talaty, Zifang Guo, Christina Reit-mann, Iain P Fraser, Raymond Evers, Dennis Swearingen, Wendy W Yeh, Joan R Butterton. Pharmacokinetic interaction between the hcv protease inhibitor mk-5172 and midazolam, pitavastatin, and atorvastatin in healthy volunteers. Hepatology. 2013; : 437-438.